Newbioideas

Mechanistic & Therapeutic insights into Motile Ciliogenesis & Respiratory dysfunction (Primary cilia dyskinesia): E2F1 increases Cilia length and number via up regulation of its target gene


AMOUNT: $ 200

Cellular and Developmental Biology, MCB Department, University of California at Berkeley, Berkeley, California, USAhas reported that“miR-34/449 miRNAs are required for motile ciliogenesis by repressing..”

This study was published in the 04 June2014Nature (IF:38.597)byProf.Lin He,Song Ruiand othersfromDivision of Cellular and Developmental Biology, MCB Department, University of California at Berkeley, Berkeley, California, USA.

On the foundation of this interesting finding,Dr L Boominathan,Director-cum-chief Scientist of GBMD,reports here that:Mechanistic & Therapeutic insights into Motile Ciliogenesis & Respiratory dysfunction (Primary cilia dyskinesia): E2F1 increases Cilia length and number via up regulation of its target gene.This study suggests that E2F1, by increasing the expression of its target gene, it could ameliorate the respiratory dysfunction found in Primary cilia dyskinesia. Together, this studysuggests thatpharmacological formulations containing “E2F-1-induced target gene”canbe used to treat Primary cilia dyskinesia.

Idea Proposed/Formulated by:Dr L Boominathan Ph.D.

Web:http://genomediscovery.org

Terms & Conditionsapplyhttp://genomediscovery.org/registration/terms-and-conditions/

To cite:Boominathan,Mechanistic & Therapeutic insights into Motile Ciliogenesis &Respiratory dysfunction(Primary cilia dyskinesia):E2F1 increases Cilia length and number via up regulation of its target gene,7/June/2014, 6.40 am,Genome-2-Bio-MedicineDiscovery center(GBMD),http://genomediscovery.org

Courtesy:When you cite drop us a line atinfo@genomediscovery.org

* Research cooperation

 

REGISTER

   

Dr.Boominathan PhD

Dr Boominathan was the first one in the world to propose a p73/p63-dependent cancer suppressor pathway (Supported by a legally valid Invention disclosure document certified by an advocate-2002/3)

Add comment

Most popular